<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838862</url>
  </required_header>
  <id_info>
    <org_study_id>16-087</org_study_id>
    <nct_id>NCT02838862</nct_id>
  </id_info>
  <brief_title>Identification of Biomarker Profiles GEP-NEN Patients</brief_title>
  <official_title>Identification of Biomarker Profiles for Individualized Prognostic Stratification and Therapy in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia (GEP-NEN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Schleswig-Holstein</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) were considered for years
      as rare tumors, their incidences are increasing. Due to their potential of early metastases
      and their heterogenous response to therapy, these tumors are important clinical entities. A
      major problem remains the impossibility to adequately predict tumors' response to treatment,
      precluding an individualized therapy. Further, there is no method to efficiently screen these
      tumors. Protein based analyses (proteomic analyses) gain in interest as methods to address
      this problematic.

      The present study was designed to investigate epidemiologic data of patients with GEP-NEN and
      to answer following questions using proteomic analysis applied to existing pathology
      specimens (paraffin-embedded specimens, FFPE): is it possible to explore protein signatures
      in this type of tumors? Is the response to therapy predictable using specific protein
      signatures? Is the tumor's tendency to metastasize related to specific protein signatures?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) were considered for years as rare
      tumors. In last years however, their incidences are increasing (3,65 / 100.000 / year)
      [Lawrence et al., 2011; Friling et al, 2014]. These tumors are important clinical entities:
      1) 40-95% of tumors have metastasized at diagnosis, 2) evidence-based data dealing with the
      therapeutic strategy and screening are still scarce.

      A central problem remains the impossibility to adequately predict the response to surgery,
      chemotherapy, radiochemotherapy, peptid-receptor-based Radiotherapy or biotherapy, precluding
      an individualized therapy (precision medicine) [Rinke et al., 2014]. An actual research topic
      in these patients is the identification of patient markers allowing an response prediction.
      Moreover, researchers try to identify tumor markers in patients with unknown primary in order
      to locate the origin of metastases. Further, identification of tumor specific markers would
      allow the development of screening strategies in GEP-NEN. Due to the ability of these
      techniques to describe the biological heterogenity of a tumor, proteomics (protein based
      analysis methods) are promising in the present problematic [Bezabeh et al., 2014; Löhr et
      al., 2006; Pan et al., 2013].

      The present study was designed to investigate epidemiologic data of patients with GEP-NEN and
      to answer following questions using proteomic analysis (MALDI-MS) applied to existing
      pathology specimens (paraffin-embedded specimens, FFPE): is it possible to explore protein
      signatures in this type of tumors? Is the response to therapy predictable using specific
      protein signatures? Is the tumor's tendency to metastasize related to specific protein
      signatures? The present investigation explores the GEP-NEN database/register of following
      institutions: University Hospital Schleswig Holstein, University hospital of Freiburg,
      Agaplesion Hospital Rotenburg. The pathology specimens of the studied register-population,
      were identified in the biobank and pathology-institutes of the participating hospitals and
      investigated using MALDI-MS technique.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response to Therapy (Surgery, Chemotherapy, Radiotherapy, etc.)</measure>
    <time_frame>12 months - 10 years (retrospective groups)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>12 months - 10 years (retrospective groups)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free Survival</measure>
    <time_frame>12 months - 10 years (retrospective groups)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>12 months - 10 years (retrospective groups)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months - 10 years (retrospective groups)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">470</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Response to Therapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>No therapy response</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      proteomic analysis (MALDI-MS) applied to existing pathology specimens of Neuroendocrine
      tumors (paraffin-embedded specimens, FFPE).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        GEP-NEN Patients registered in the institutional NEN Registries
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GEP-NEN

        Exclusion Criteria:

          -  Absence of histological confirmation of the diagnosis

          -  Absence of pathology specimen to evaluate using MALDI-MS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Keck, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Lübeck - Department of Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franck G Billmann, MD, PhD</last_name>
    <phone>+494515001917</phone>
    <email>Franck.Billmann@uksh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrich Wellner, MD</last_name>
    <email>Ulrich.Wellner@uksh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Freiburg - Department of Surgery</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Thomusch, MD</last_name>
      <email>Oliver.Thomusch@uniklinik-freiburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital SH - Campus Lübeck - Department of Surgery</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck Billmann, MD, PhD</last_name>
      <phone>+494515001917</phone>
      <email>Franck.Billmann@uksh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agaplesion Diakonieklinikum Rotenburg - Department of Surgery</name>
      <address>
        <city>Rotenburg</city>
        <zip>27356</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Khatib-Chahidi, MD</last_name>
      <phone>+494261772066</phone>
      <email>Karl.Khatib-Chahidi@diako-online.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Bezabeh T, Ijare OB, Nikulin AE, Somorjai RL, Smith IC. MRS-based Metabolomics in Cancer Research. Magn Reson Insights. 2014 Feb 13;7:1-14. doi: 10.4137/MRI.S13755. eCollection 2014. Review.</citation>
    <PMID>25114549</PMID>
  </reference>
  <reference>
    <citation>Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R; Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014 Jan;15(1):e8-21. doi: 10.1016/S1470-2045(13)70362-0. Review.</citation>
    <PMID>24384494</PMID>
  </reference>
  <reference>
    <citation>Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii. doi: 10.1016/j.ecl.2010.12.005. Review.</citation>
    <PMID>21349409</PMID>
  </reference>
  <reference>
    <citation>Löhr JM, Faissner R, Findeisen P, Neumaier M. [Proteome analysis--basis for individualized pancreatic carcinoma therapy?]. Internist (Berl). 2006 Jun;47 Suppl 1:S40-8. Review. German.</citation>
    <PMID>16773365</PMID>
  </reference>
  <reference>
    <citation>Pan S, Brentnall TA, Kelly K, Chen R. Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges. Proteomics. 2013 Feb;13(3-4):710-21. doi: 10.1002/pmic.201200319. Epub 2013 Jan 7. Review.</citation>
    <PMID>23125171</PMID>
  </reference>
  <reference>
    <citation>Rinke A, Arnold R. Aktuelle Therapie neuroendokriner Tumoren. Arzneimitteltherapie 2014;32:2-13</citation>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Schleswig-Holstein</investigator_affiliation>
    <investigator_full_name>Franck Billmann</investigator_full_name>
    <investigator_title>Director Section for Endocrine Surgery</investigator_title>
  </responsible_party>
  <keyword>Neuroendocrine Tumors</keyword>
  <keyword>MALDI-MS</keyword>
  <keyword>Proteomics</keyword>
  <keyword>Biomarkers, Tumor</keyword>
  <keyword>Precision Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

